Atara Biotherapeutics Inc (ATRA) Insider Sells $59,175.00 in Stock

Share on StockTwits

Atara Biotherapeutics Inc (NASDAQ:ATRA) insider Joe Newell sold 1,500 shares of the stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $39.45, for a total transaction of $59,175.00. Following the completion of the transaction, the insider now owns 33,358 shares in the company, valued at approximately $1,315,973.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Joe Newell also recently made the following trade(s):

  • On Wednesday, August 1st, Joe Newell sold 1,500 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $37.74, for a total transaction of $56,610.00.
  • On Monday, July 30th, Joe Newell sold 10,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $35.78, for a total transaction of $357,800.00.

Shares of NASDAQ ATRA traded up $1.35 during midday trading on Friday, reaching $39.75. 929,610 shares of the stock were exchanged, compared to its average volume of 470,808. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -9.94 and a beta of 2.54. Atara Biotherapeutics Inc has a twelve month low of $12.65 and a twelve month high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.17). equities analysts forecast that Atara Biotherapeutics Inc will post -4.58 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ATRA. Riverhead Capital Management LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $100,000. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $107,000. Great West Life Assurance Co. Can lifted its position in shares of Atara Biotherapeutics by 100.1% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 1,655 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at approximately $180,000. Finally, Highland Private Wealth Management purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at approximately $202,000.

A number of brokerages have recently commented on ATRA. BidaskClub cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, August 3rd. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 27th. Finally, Citigroup dropped their price objective on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research note on Monday, June 11th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $43.17.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: What do I need to know about analyst ratings?

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply